Company Overview: GILD

GILD Overview

Upcoming Projects (GILD)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (GILD)

A Third Look: Discussing Gilead’s Livdelzi (seladelpar) recently approved for treatment of primary biliary cholangitis (PBC) in patients who have an inadequate response to UDCA or are unable to tolerate UDCA
Ticker: GILD
Executed On: Oct 10, 2024 at 04:15 PM EDT
A Second Look: Discussing Gilead’s Livdelzi (seladelpar) recently approved for treatment of primary biliary cholangitis (PBC) in patients who have an inadequate response to UDCA or are unable to tolerate UDCA
Ticker: GILD
Executed On: Sep 11, 2024 at 09:00 AM EDT
Discussing Gilead’s Livdelzi (seladelpar) recently approved for treatment of primary biliary cholangitis (PBC) in patients who have an inadequate response to UDCA or are unable to tolerate UDCA
Ticker: GILD
Executed On: Aug 29, 2024 at 08:00 AM EDT
A Third Look: Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Tickers: GSK, GILD
Executed On: Aug 22, 2024 at 03:00 PM EDT
A Second Look: Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Tickers: GSK, GILD
Executed On: Aug 01, 2024 at 04:00 PM EDT
Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Tickers: GSK, GILD
Executed On: Jul 31, 2024 at 09:30 AM EDT
A Third View: Digging into Gilead's twice-yearly Lenacapavir 100 percent efficacy compared to daily Truvada for HIV
Ticker: GILD
Executed On: Jul 11, 2024 at 10:00 AM EDT
A Second View: Digging into Gilead's twice-yearly Lenacapavir 100 percent efficacy compared to daily Truvada for HIV
Ticker: GILD
Executed On: Jul 02, 2024 at 05:00 PM EDT
Digging into Gilead's twice-yearly Lenacapavir 100 percent efficacy compared to daily Truvada for HIV
Ticker: GILD
Executed On: Jul 02, 2024 at 10:00 AM EDT
A Third Opinion: Discussing the potential of Gildead's Seladelpar in PBC after their interim analysis from the ASSURE study
Tickers: GILD, CBAY
Executed On: Jun 14, 2024 at 10:00 AM EDT
A Second Opinion: Discussing the potential of Gildead's Seladelpar in PBC after their interim analysis from the ASSURE study
Tickers: GILD, CBAY
Executed On: Jun 11, 2024 at 03:00 PM EDT
Discussing the potential of Gildead's Seladelpar in PBC after their interim analysis from the ASSURE study
Tickers: GILD, CBAY
Executed On: Jun 05, 2024 at 10:30 AM EDT
A Third Look: Discussing the FDA approved label update for Biktarvy to include pregnant adults with HIV based on the additional data from Study 5310.
Ticker: GILD
Executed On: May 10, 2024 at 10:00 AM EDT
A Second Look: Discussing the FDA approved label update for Biktarvy to include pregnant adults with HIV based on the additional data from Study 5310.
Ticker: GILD
Executed On: May 09, 2024 at 11:30 AM EDT
Discussing the FDA approved label update for Biktarvy to include pregnant adults with HIV based on the additional data from Study 5310.
Ticker: GILD
Executed On: May 08, 2024 at 04:30 PM EDT
A Third Look: Discussing the safety profile and potential use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.
Ticker: GILD
Executed On: Sep 22, 2023 at 03:00 PM EDT
A Second Look: Discussing the safety profile and potential use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.
Ticker: GILD
Executed On: Sep 12, 2023 at 10:00 AM EDT
Discussing the safety profile and potential use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.
Ticker: GILD
Executed On: Sep 07, 2023 at 05:00 PM EDT
Discussing the potential of domvanalimab, the first Fc-silent anti-TIGIT monoclonal antibody, and the results from the ARC-7 study of domvanalimab as first-line treatment in metastatic NSCLC presented at the 2023 ASCO meeting
Ticker: GILD
Executed On: Jun 20, 2023 at 12:30 PM EDT
Examining the multiple myeloma treatment landscape and the potential use of CART-ddBCMA currently in phase 1 trial by Gilead Science and Arcellx presented at the ASH Conference
Tickers: GILD, ACLX
Executed On: Feb 14, 2023 at 01:00 PM EST
A Second View: Understanding the potential of TIGIT targeting drugs in treating advanced or recurrent cancers, such as Gilead's domvanalimab for treating metastatic lung cancer.
Ticker: GILD
Executed On: Jan 31, 2023 at 03:30 PM EST
Understanding the potential of TIGIT targeting drugs in treating advanced or recurrent cancers, such as Gilead's domvanalimab for treating metastatic lung cancer.
Ticker: GILD
Executed On: Jan 27, 2023 at 04:00 PM EST
A Third Look at lenacapavir as a capsid inhibitor for HIV
Ticker: GILD
Executed On: Jan 19, 2023 at 04:00 PM EST
A Second Look at lenacapavir as a capsid inhibitor for HIV
Ticker: GILD
Executed On: Jan 18, 2023 at 04:30 PM EST
A Look at lenacapavir as a capsid inhibitor for HIV
Ticker: GILD
Executed On: Jan 10, 2023 at 01:00 PM EST
The current treatment landscape for HDV and new therapies in development including Lonafarnib in development from Eiger Bio and Bulevirtide by Gilead Sciences which was recently rejected by the FDA
Tickers: EIGR, GILD
Executed On: Dec 12, 2022 at 05:00 PM EST
Discussing the potential of Obe-cel(AUTO1), a CD19 CAR T cell therapy being investigated for treatment in adult patients with acute lymphoblastic leukemia(ALL) and it's ongoing Phase 1/2 FELIX trial
Tickers: AUTL, AMGN, GILD, PFE
Executed On: Oct 07, 2022 at 02:00 PM EDT
A third look at the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Tickers: GILD, AZN, DSNKY
Executed On: Oct 06, 2022 at 04:00 PM EDT
Discussing the P2 acelERA BC study of Giredestrant in patients with ER+, HER2– locally advanced/metastatic breast cancer and the AMEERA-3 Phase 2 study of amcenestrant in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Tickers: SNY, RHHBY, GILD, AZN, DSKYN
Executed On: Oct 04, 2022 at 10:00 AM EDT
A second look at the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Tickers: GILD, AZN, DSNKY
Executed On: Sep 28, 2022 at 05:00 PM EDT
A look at the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Tickers: GILD, AZN, DSNKY
Executed On: Sep 23, 2022 at 09:00 AM EDT
A Fourth Opinion: Discussing the current HIV treatment landscape and specifically how other treatment options compare to Gilead Sciences' HIV treatments
Ticker: GILD
Executed On: Aug 10, 2022 at 10:00 AM EDT
A Third Look: Discussing the current HIV treatment landscape and specifically how other treatment options compare to Gilead Sciences' HIV treatments
Ticker: GILD
Executed On: Aug 09, 2022 at 03:00 PM EDT
A Second Opinion: Discussing the current HIV treatment landscape and specifically how other treatment options compare to Gilead Sciences' HIV treatments
Ticker: GILD
Executed On: Aug 08, 2022 at 04:30 PM EDT
Discussing the current HIV treatment landscape and specifically how other treatment options compare to Gilead Sciences' HIV treatments
Ticker: GILD
Executed On: Aug 05, 2022 at 06:00 PM EDT
A Final look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: Jun 14, 2022 at 04:30 PM EDT
A third look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: Jun 02, 2022 at 02:30 PM EDT
A second look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: Jun 01, 2022 at 01:00 PM EDT
A look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: May 31, 2022 at 03:00 PM EDT

Upcoming & Overdue Catalysts (GILD)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (GILD)

Don’t see a strategic initiative related to the company you care about? Create your own!